Amycretin, Novo Nordisks oral dual GLP-1/amylin agonist, showed 13% weight loss in early trials, signaling a move toward multi-pathway oral therapies
Unfortunately, vitamin B12 deficiency during infancy results in severe, permanent neurological damage
Endocrinologists and diabetologists built the category
For many patients, especially those whose primary challenge is appetite control, this mechanism is sufficient to support meaningful and sustainable weight loss
FDA-approved GLP-1 receptor agonists include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin), exenatide (Bydureon BCise), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist